US6458772B1
(en)
*
|
1909-10-07 |
2002-10-01 |
Medivir Ab |
Prodrugs
|
DE3623397A1
(de)
*
|
1986-07-11 |
1988-01-14 |
Boehringer Mannheim Gmbh |
Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
|
EP0317505A1
(de)
*
|
1987-11-13 |
1989-05-24 |
Ciba-Geigy Ag |
Neue Azacycloalkylalkandiphosphonsäuren
|
ES2054868T3
(es)
*
|
1987-12-11 |
1994-08-16 |
Ciba Geigy Ag |
Acidos aralifatilaminoalcanodifosfonicos.
|
US5190930A
(en)
*
|
1987-12-11 |
1993-03-02 |
Ciba-Geigy Corporation |
Araliphatylaminoalkanediphosphonic acids
|
US5110807A
(en)
*
|
1988-12-01 |
1992-05-05 |
Ciba-Geigy Corporation |
Araliphatylaminoalkanediphosphonic acids
|
JPH07629B2
(ja)
*
|
1988-01-20 |
1995-01-11 |
山之内製薬株式会社 |
(シクロアルキルアミノ)メチレンビス(フォスフォン酸)および該化合物を有効成分とする医薬
|
US4933472A
(en)
*
|
1988-04-08 |
1990-06-12 |
Yamanouchi Pharmaceutical Co., Ltd. |
Substituted aminomethylenebis(phosphonic acid) derivatives
|
DE3822650A1
(de)
*
|
1988-07-05 |
1990-02-01 |
Boehringer Mannheim Gmbh |
Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
|
DE68926310T2
(de)
*
|
1988-11-01 |
1996-10-24 |
Arch Dev Corp |
Verfahren zur abtrennung von metallischen ionen mit phosphonsäuren als complexbildner
|
GB8825589D0
(en)
*
|
1988-11-02 |
1988-12-07 |
Albright & Wilson |
Purification
|
TW198039B
(xx)
*
|
1988-11-28 |
1993-01-11 |
Ciba Geigy Ag |
|
US5154843A
(en)
*
|
1989-02-08 |
1992-10-13 |
The Lubrizol Corporation |
Hydroxyalkane phosphonic acids and derivatives thereof and lubricants containing the same
|
PH26923A
(en)
*
|
1989-03-08 |
1992-12-03 |
Ciba Geigy |
N-substituted amino alkanediphosphonic acids
|
US4987767A
(en)
*
|
1989-06-09 |
1991-01-29 |
Research Corporation Technologies, Inc. |
Exposive detection screening system
|
US5139786A
(en)
*
|
1989-07-07 |
1992-08-18 |
Ciba-Geigy Corporation |
Topical formulations
|
MX21453A
(es)
*
|
1989-07-07 |
1994-01-31 |
Ciba Geigy Ag |
Preparaciones farmaceuticas que se administran en forma topica.
|
MX21452A
(es)
*
|
1989-07-07 |
1994-01-31 |
Ciba Geigy Ag |
Preparaciones farmaceuticas que se administran en forma topica.
|
US5487897A
(en)
*
|
1989-07-24 |
1996-01-30 |
Atrix Laboratories, Inc. |
Biodegradable implant precursor
|
US5324519A
(en)
*
|
1989-07-24 |
1994-06-28 |
Atrix Laboratories, Inc. |
Biodegradable polymer composition
|
EP0416689B1
(en)
*
|
1989-09-06 |
1995-11-29 |
Merck & Co. Inc. |
Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
|
US5356887A
(en)
*
|
1990-01-31 |
1994-10-18 |
Merck & Co., Inc. |
Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
|
FI89364C
(fi)
*
|
1990-12-20 |
1993-09-27 |
Leiras Oy |
Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat
|
IT1244698B
(it)
*
|
1991-02-01 |
1994-08-08 |
Gentili Ist Spa |
Acidi aril-o arilalchil-acil ammino-alchil-idrossidifosfonici, procedimento per la loro preparazione e loro uso in terapia osteo-articolare e dei tessuti connettori in generale
|
CA2102303A1
(en)
*
|
1991-06-19 |
1992-12-20 |
Roy Allen Johnson |
Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents
|
IT1247034B
(it)
*
|
1991-06-26 |
1994-12-12 |
Gentili Ist Spa |
Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
|
ATE147396T1
(de)
*
|
1991-08-27 |
1997-01-15 |
Ciba Geigy Ag |
N-substituierte aminomethandiphosphonsäuren
|
EP0541037A3
(en)
*
|
1991-11-06 |
1997-02-26 |
Takeda Chemical Industries Ltd |
Squalene synthetase inhibitory composition and use thereof
|
DE4228552A1
(de)
*
|
1992-08-27 |
1994-03-03 |
Boehringer Mannheim Gmbh |
Diphosphonsäuren und deren Salze enthaltende Arzneimittel
|
AU670337B2
(en)
|
1992-11-30 |
1996-07-11 |
Novartis Ag |
Use of certain methanebisphosphonic acid derivatives in fracture healing
|
EP0600834A1
(en)
*
|
1992-11-30 |
1994-06-08 |
Ciba-Geigy Ag |
Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
|
US5358941A
(en)
*
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
US6406714B1
(en)
|
1992-12-02 |
2002-06-18 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids
|
DE59309360D1
(de)
*
|
1992-12-02 |
1999-03-18 |
Hoechst Ag |
Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
|
EP0675723A4
(en)
*
|
1992-12-23 |
1998-08-05 |
Merck & Co Inc |
BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
|
US6399592B1
(en)
|
1992-12-23 |
2002-06-04 |
Merck & Co., Inc. |
Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
|
US5728650A
(en)
*
|
1993-10-07 |
1998-03-17 |
Zeneca Limited |
Herbicidal aza bisphosphonic acids and compositions containing the same
|
TW401276B
(en)
*
|
1993-10-07 |
2000-08-11 |
Zeneca Ltd |
Novel compounds and a method of controlling growth of plants
|
US5591730A
(en)
*
|
1993-10-12 |
1997-01-07 |
The Regents Of The University Of California |
Inhibition of urinary calculi growth
|
US5681873A
(en)
*
|
1993-10-14 |
1997-10-28 |
Atrix Laboratories, Inc. |
Biodegradable polymeric composition
|
US20010007863A1
(en)
*
|
1998-06-18 |
2001-07-12 |
Merck & Co., Inc. |
Wet granulation formulation for bisphosphonic acids
|
US5780455A
(en)
*
|
1994-08-24 |
1998-07-14 |
Merck & Co., Inc. |
Intravenous alendronate formulations
|
EP0831756A1
(en)
|
1995-06-06 |
1998-04-01 |
Merck & Co., Inc. |
Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
|
EP0753523A1
(en)
*
|
1995-07-10 |
1997-01-15 |
Gador S.A. |
Amino-substituted bisphosphonic acids
|
WO1997012619A1
(en)
*
|
1995-09-29 |
1997-04-10 |
Novartis Ag |
Method of treating the navicular disease in horses
|
GB9607945D0
(en)
*
|
1996-04-17 |
1996-06-19 |
Univ Nottingham |
Bisphosponates as Anti-inflammatory agents
|
DE19615812A1
(de)
*
|
1996-04-20 |
1997-10-23 |
Boehringer Mannheim Gmbh |
Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
|
KR100192215B1
(ko)
*
|
1996-09-03 |
1999-06-15 |
강재헌 |
3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
|
DE19719680A1
(de)
|
1997-05-09 |
1998-11-19 |
Boehringer Mannheim Gmbh |
Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
US6432932B1
(en)
|
1997-07-22 |
2002-08-13 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
US5994329A
(en)
|
1997-07-22 |
1999-11-30 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
US6255359B1
(en)
|
1997-12-23 |
2001-07-03 |
Board Of Regents Of The University Of Texas System |
Permeable compositions and methods for their preparation
|
US6187329B1
(en)
|
1997-12-23 |
2001-02-13 |
Board Of Regents Of The University Of Texas System |
Variable permeability bone implants, methods for their preparation and use
|
CN1061661C
(zh)
*
|
1997-12-24 |
2001-02-07 |
国家医药管理局上海医药工业研究院 |
(环庚基胺基)亚甲基二膦酸二钠一水合物制备方法
|
US20020128301A1
(en)
*
|
1998-02-13 |
2002-09-12 |
Medivir AB |
Non-nucleoside reverse transcriptase inhibitors
|
ES2359973T3
(es)
*
|
1998-03-19 |
2011-05-30 |
MERCK SHARP & DOHME CORP. |
Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
|
US7128927B1
(en)
|
1998-04-14 |
2006-10-31 |
Qlt Usa, Inc. |
Emulsions for in-situ delivery systems
|
EP0998933A1
(de)
|
1998-10-09 |
2000-05-10 |
Boehringer Mannheim Gmbh |
Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
|
EP0998932A1
(de)
|
1998-10-09 |
2000-05-10 |
Boehringer Mannheim Gmbh |
Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
|
KR100453779B1
(ko)
|
1998-12-04 |
2004-10-20 |
로쉐 디아그노스틱스 게엠베하 |
내인공삽입물의 골형성을 개선시키기 위한 이밴드론산염의용도
|
HUP0201329A3
(en)
*
|
1999-05-21 |
2005-02-28 |
Novartis Ag |
Use of bisphosphonic acids for treating angiogenesis
|
AR024462A1
(es)
|
1999-07-01 |
2002-10-02 |
Merck & Co Inc |
Tabletas farmaceuticas
|
US8226598B2
(en)
*
|
1999-09-24 |
2012-07-24 |
Tolmar Therapeutics, Inc. |
Coupling syringe system and methods for obtaining a mixed composition
|
AR021347A1
(es)
|
1999-10-20 |
2002-07-17 |
Cipla Ltd |
Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
|
US6677320B2
(en)
|
2000-01-20 |
2004-01-13 |
Hoffmann-La Roches Inc. |
Parenteral bisphosphonate composition with improved local tolerance
|
US6410520B2
(en)
|
2000-02-01 |
2002-06-25 |
The Procter & Gamble Company |
Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
|
PE20011065A1
(es)
|
2000-02-01 |
2001-11-21 |
Procter & Gamble |
Proceso para fabricar bisfosfonatos geminales
|
SE0000382D0
(sv)
|
2000-02-07 |
2000-02-07 |
Astrazeneca Ab |
New process
|
CN1180846C
(zh)
|
2000-05-05 |
2004-12-22 |
霍夫曼-拉罗奇有限公司 |
含有双膦酸或其盐的,用于皮下给药的凝胶体状药物组合物
|
TWI315982B
(en)
*
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
US20050070504A1
(en)
*
|
2001-12-21 |
2005-03-31 |
The Procter & Gamble Co. |
Risedronate compositions and their methods of use
|
WO2003055496A1
(en)
*
|
2001-12-21 |
2003-07-10 |
The Procter & Gamble Company |
Method for the treatment of bone disorders
|
CA2472578A1
(en)
*
|
2002-01-24 |
2003-07-31 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Anti-cancer combination and use thereof
|
JP2005531532A
(ja)
*
|
2002-04-05 |
2005-10-20 |
メルク エンド カムパニー インコーポレーテッド |
アレンドロナートおよびビタミンd製剤を用いる骨吸収阻害法
|
CA2481142C
(en)
|
2002-05-10 |
2012-11-13 |
F.Hoffmann-La Roche Ag |
Bisphosphonic acids for the treatment and prevention of osteoporosis
|
DE60331724D1
(de)
*
|
2002-05-17 |
2010-04-29 |
Teva Pharma |
Verwendung von bestimmten lösungsmitteln zur herstellung von bisphosphonsäuren
|
JP2005534653A
(ja)
*
|
2002-06-06 |
2005-11-17 |
メルク フロスト カナダ アンド カンパニー |
眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体
|
WO2004019938A1
(en)
*
|
2002-08-28 |
2004-03-11 |
Merck Frosst Canada & Co. |
Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
US20040097468A1
(en)
*
|
2002-11-20 |
2004-05-20 |
Wimalawansa Sunil J. |
Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
|
JP4427453B2
(ja)
|
2002-12-20 |
2010-03-10 |
エフ.ホフマン−ラ ロシュ アーゲー |
高用量イバンドロネート製剤
|
WO2004065397A1
(en)
*
|
2003-01-17 |
2004-08-05 |
Teva Pharmaceutical Industries Ltd. |
Risedronate sodium having a very low content of iron
|
ATE451380T1
(de)
*
|
2003-08-21 |
2009-12-15 |
Sun Pharmaceuticals Ind Ltd |
Verfahren zur herstellung von bisphosphonsäureverbindungen
|
US7312353B2
(en)
|
2003-08-21 |
2007-12-25 |
Merck Frost Canada & Co. |
Cathespin cysteine protease inhibitors
|
JP2007505886A
(ja)
*
|
2003-09-19 |
2007-03-15 |
ファイザー・プロダクツ・インク |
2−メチレン−19−ノル−ビタミンd誘導体及びビスホスフォネートの組み合わせを含む医薬組成物及び方法
|
US7723542B2
(en)
|
2003-12-23 |
2010-05-25 |
Trifarma S.P.A. |
Process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
US20050261250A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Merck & Co., Inc., |
Compositions and methods for inhibiting bone resorption
|
CN1956706A
(zh)
|
2004-05-24 |
2007-05-02 |
宝洁公司 |
包含一种螯合剂的双膦酸酯肠溶固体口服剂型
|
UA87854C2
(xx)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена
|
WO2006002348A2
(en)
*
|
2004-06-23 |
2006-01-05 |
Teva Pharmaceutical Industies Ltd. |
Solid and crystalline ibandronic acid
|
CA2576659A1
(en)
|
2004-08-23 |
2006-03-02 |
Teva Pharmaceutical Industries Ltd. |
Solid and crystalline ibandronate sodium and processes for preparation thereof
|
WO2007109585A2
(en)
*
|
2006-03-17 |
2007-09-27 |
The Board Of Trustees Of The University Of Illinois |
Bisphosphonate compounds and methods
|
US8012949B2
(en)
*
|
2004-10-08 |
2011-09-06 |
The Board Of Trustees Of The University Of Illinois |
Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
|
WO2006039721A2
(en)
*
|
2004-10-08 |
2006-04-13 |
The Board Of Trustees Of The University Of Illinois |
Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
|
US7214818B2
(en)
*
|
2004-10-29 |
2007-05-08 |
Hoffmann-La Roche Inc. |
Method for synthesizing bisphosphonate
|
EP1832293A4
(en)
*
|
2004-12-10 |
2009-01-07 |
Tmrc Co Ltd |
MEANS FOR THE TREATMENT OF CANCER METASTAS AND CANNESMAS TREATMENT
|
ES2478302T3
(es)
*
|
2005-02-01 |
2014-07-21 |
F. Hoffmann-La Roche Ag |
Polimorfo A de Ibandronato
|
MX2007008917A
(es)
*
|
2005-02-01 |
2007-08-21 |
Hoffmann La Roche |
Polimorfo b de ibandronato.
|
CA2599572A1
(en)
|
2005-03-02 |
2007-04-26 |
Merck & Co., Inc. |
Composition for inhibition of cathepsin k
|
AU2006227399A1
(en)
*
|
2005-03-17 |
2006-09-28 |
Elan Pharma International Limited |
Nanoparticulate biphosphonate compositions
|
EP1865967A4
(en)
*
|
2005-04-08 |
2011-02-09 |
Chimerix Inc |
COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
|
US8642577B2
(en)
|
2005-04-08 |
2014-02-04 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
WO2007013097A1
(en)
*
|
2005-07-25 |
2007-02-01 |
Natco Pharma Limited |
Improved process for the preparation of ibandronate sodium
|
US8362086B2
(en)
|
2005-08-19 |
2013-01-29 |
Merial Limited |
Long acting injectable formulations
|
US20070049557A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
WO2007074475A2
(en)
*
|
2005-12-27 |
2007-07-05 |
Natco Pharma Limited |
Novel polymorphic forms of ibandronate
|
US20070191315A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Bengt Bergstrom |
Method for administering ibandronate
|
DE602007007773D1
(de)
|
2006-06-23 |
2010-08-26 |
Cipla Ltd |
Verfahren zur synthese von ibandronat-natrium
|
KR101081149B1
(ko)
|
2006-09-07 |
2011-11-07 |
에미스페어 테크놀로지스, 인코포레이티드 |
Snac(살카프로제이트 나트륨)의 제조 방법
|
WO2008060609A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ibandronate sodium
|
US20080139514A1
(en)
*
|
2006-11-29 |
2008-06-12 |
Subhash Pandurang Gore |
Diphosphonic acid pharmaceutical compositions
|
CA2570949A1
(en)
*
|
2006-12-12 |
2008-06-12 |
Apotex Pharmachem Inc. |
Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
|
AU2007335156A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Mylan Pharmaceuticals Ulc |
Pharmaceutical composition comprising a hot-melt granulated lubricant
|
US20100179110A1
(en)
*
|
2006-12-20 |
2010-07-15 |
Mostafa Akbarieh |
Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
|
US20100144679A1
(en)
*
|
2007-03-21 |
2010-06-10 |
Duke University |
Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
|
CA2683971C
(en)
*
|
2007-04-11 |
2013-02-26 |
F. Hoffmann-La Roche Ag |
Multi step systhesis of ibandronate
|
JP2010523709A
(ja)
*
|
2007-04-12 |
2010-07-15 |
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ |
Fpps、ggpps及びdppsを含む複数の標的に対して高い効能を有するビスホスホネート化合物及び方法
|
EP2316840A1
(en)
|
2007-04-19 |
2011-05-04 |
Dr. Reddy's Laboratories Limited |
Ibandronate Sodium Polymorphs
|
WO2009020483A1
(en)
*
|
2007-08-09 |
2009-02-12 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ibandronate sodium
|
JP2010536437A
(ja)
|
2007-08-15 |
2010-12-02 |
カーディオデックス リミテッド |
穿刺を閉塞するためのシステムおよび方法
|
US20090075944A1
(en)
*
|
2007-09-15 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched ibandronate
|
US20090099390A1
(en)
*
|
2007-09-24 |
2009-04-16 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ibandronic acid and processes for the preparation thereof
|
EP2128166A1
(en)
|
2008-05-20 |
2009-12-02 |
Chemo Ibérica, S.A. |
Polymorphic forms of Ibandronate sodium and processes for preparation thereof
|
WO2009061336A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Teva Pharmaceutical Industries Ltd. |
Amorphous and crystalline forms of ibandronate disodium
|
AU2008350907A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
EP2489656A1
(en)
|
2007-12-21 |
2012-08-22 |
Ligand Pharmaceuticals Inc. |
Selective androgen receptor modulators (sarms) and uses thereof
|
WO2009093258A2
(en)
*
|
2008-01-24 |
2009-07-30 |
Fleming Laboratories Limited |
A new and improved process for the preparation of ibandronate sodium monohydrate
|
MX2010008148A
(es)
*
|
2008-01-25 |
2010-10-20 |
Chimerix Inc |
Métodos de tratamiento de infecciones virales.
|
WO2010035664A1
(ja)
*
|
2008-09-24 |
2010-04-01 |
田辺三菱製薬株式会社 |
ビスホスホン酸誘導体の製法
|
EP2180003A1
(en)
|
2008-10-21 |
2010-04-28 |
Zentiva, k.s. |
Preparation of ibandronate trisodium
|
EP2210596A1
(en)
|
2009-01-22 |
2010-07-28 |
Laboratorios Liconsa, S.A. |
Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
|
GB0906068D0
(en)
|
2009-04-07 |
2009-05-20 |
King S College London |
Bisphosphonate Compounds for chelating radionuclides
|
EP2440250A1
(en)
|
2009-06-11 |
2012-04-18 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
US8614200B2
(en)
|
2009-07-21 |
2013-12-24 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
US20120164104A1
(en)
|
2009-08-03 |
2012-06-28 |
Chimerix, Inc. |
Composition and Methods of Treating Viral Infections and Viral Induced Tumors
|
WO2011016738A1
(en)
|
2009-08-05 |
2011-02-10 |
Zaklady Farmaceutyczne Polpharma Sa |
A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
|
WO2011028737A2
(en)
|
2009-09-01 |
2011-03-10 |
Duke University |
Bisphosphonate compositions and methods for treating heart failure
|
FR2954320B1
(fr)
|
2009-12-17 |
2012-06-15 |
Cll Pharma |
Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
|
WO2011100698A2
(en)
|
2010-02-12 |
2011-08-18 |
Chimerix, Inc. |
Methods of treating viral infection
|
CA2797601A1
(en)
|
2010-04-26 |
2011-11-10 |
Chimerix, Inc. |
Methods of treating retroviral infections and related dosage regimes
|
EP2609101B1
(en)
|
2010-07-14 |
2015-01-28 |
Pharmathen S.A. |
Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
|
TR201100151A2
(tr)
|
2011-01-06 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
İbandronate formülasyonu.
|
EP2675440B1
(en)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
PL2731591T3
(pl)
|
2011-07-13 |
2021-05-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Liposomy zawierające bisfosfonian i środek amfipatyczny w wyniku ko-enkapsulacji
|
US9949992B2
(en)
|
2011-11-16 |
2018-04-24 |
Duke University |
Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
|
US8748097B1
(en)
|
2011-12-02 |
2014-06-10 |
President And Fellows Of Harvard College |
Identification of agents for treating calcium disorders and uses thereof
|
TR201200588A2
(tr)
|
2012-01-18 |
2012-07-23 |
Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ |
Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
|
GB201200868D0
(en)
|
2012-01-19 |
2012-02-29 |
Depuy Int Ltd |
Bone filler composition
|
CN103396332A
(zh)
*
|
2013-08-19 |
2013-11-20 |
四川协力制药有限公司 |
3—[(n—甲基—n—戊基)氨基]丙酸盐酸盐的制备方法
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
CN105593230B
(zh)
|
2013-10-08 |
2018-07-06 |
默沙东公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
PL407922A1
(pl)
|
2014-04-16 |
2015-10-26 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością |
Nowe bisfosfoniany i ich zastosowanie
|
KR20160147007A
(ko)
|
2014-05-30 |
2016-12-21 |
화이자 인코포레이티드 |
선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
|
KR20200066690A
(ko)
|
2017-10-16 |
2020-06-10 |
칭화대학교 |
메발로네이트 경로 억제제 및 이의 약제학적 조성물
|
KR20200085441A
(ko)
|
2019-01-07 |
2020-07-15 |
엠에프씨 주식회사 |
이반드로네이트의 신규한 결정형 및 이의 제조방법
|
KR20220115062A
(ko)
|
2021-02-09 |
2022-08-17 |
(주)오스티오뉴로젠 |
크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|